VOYAGER THERAPEUTICS INC (VYGR) Stock Fundamental Analysis
NASDAQ:VYGR - Nasdaq - US92915B1061 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to VYGR. VYGR was compared to 555 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VYGR as it has an excellent financial health rating, but there are worries on the profitability. VYGR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
VYGR had negative earnings in the past year.
VYGR had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VYGR reported negative net income in multiple years.
In the past 5 years VYGR reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of VYGR (-23.98%) is better than 75.14% of its industry peers.
VYGR has a better Return On Equity (-31.06%) than 76.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.98% | ||
| ROE | -31.06% | ||
| ROIC | N/A |
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VYGR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
VYGR has more shares outstanding than it did 1 year ago.
VYGR has more shares outstanding than it did 5 years ago.
VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -0.14, we must say that VYGR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VYGR (-0.14) is better than 61.44% of its industry peers.
There is no outstanding debt for VYGR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.14 |
ROIC/WACCN/A
WACC9.63%
2.3 Liquidity
A Current Ratio of 6.10 indicates that VYGR has no problem at all paying its short term obligations.
VYGR's Current ratio of 6.10 is fine compared to the rest of the industry. VYGR outperforms 61.62% of its industry peers.
VYGR has a Quick Ratio of 6.10. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.10, VYGR is doing good in the industry, outperforming 62.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.1 | ||
| Quick Ratio | 6.1 |
3. Growth
3.1 Past
VYGR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2820.00%.
Looking at the last year, VYGR shows a very negative growth in Revenue. The Revenue has decreased by -43.77% in the last year.
The Revenue has been decreasing by -5.18% on average over the past years.
EPS 1Y (TTM)-2820%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-165%
Revenue 1Y (TTM)-43.77%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-66.83%
3.2 Future
The Earnings Per Share is expected to decrease by -0.68% on average over the next years.
VYGR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -3.32% yearly.
EPS Next Y-91.02%
EPS Next 2Y-22.94%
EPS Next 3Y-10.31%
EPS Next 5Y-0.68%
Revenue Next Year-57.23%
Revenue Next 2Y-12.53%
Revenue Next 3Y-7.48%
Revenue Next 5Y-3.32%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VYGR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYGR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VYGR's earnings are expected to decrease with -10.31% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.94%
EPS Next 3Y-10.31%
5. Dividend
5.1 Amount
VYGR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.2
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners63.59%
Inst Owner Change0.94%
Ins Owners0.92%
Ins Owner Change2.73%
Market Cap177.09M
Analysts87.78
Price Target16.32 (410%)
Short Float %8.51%
Short Ratio6.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-36.79%
Min EPS beat(2)-57.86%
Max EPS beat(2)-15.73%
EPS beat(4)2
Avg EPS beat(4)12.19%
Min EPS beat(4)-57.86%
Max EPS beat(4)65.43%
EPS beat(8)6
Avg EPS beat(8)80.18%
EPS beat(12)8
Avg EPS beat(12)90.86%
EPS beat(16)10
Avg EPS beat(16)73.56%
Revenue beat(2)0
Avg Revenue beat(2)-58.03%
Min Revenue beat(2)-62.87%
Max Revenue beat(2)-53.19%
Revenue beat(4)2
Avg Revenue beat(4)48.38%
Min Revenue beat(4)-62.87%
Max Revenue beat(4)206.51%
Revenue beat(8)6
Avg Revenue beat(8)109.69%
Revenue beat(12)8
Avg Revenue beat(12)102.96%
Revenue beat(16)9
Avg Revenue beat(16)70.44%
PT rev (1m)17.43%
PT rev (3m)-0.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.47%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.42%
Revenue NQ rev (1m)-4.8%
Revenue NQ rev (3m)-37.28%
Revenue NY rev (1m)-22.04%
Revenue NY rev (3m)-43.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.65 | ||
| P/tB | 0.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.46
EYN/A
EPS(NY)-1.71
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS1.21
BVpS4.93
TBVpS4.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.98% | ||
| ROE | -31.06% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 44.8% | ||
| Cap/Sales | 3.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.1 | ||
| Quick Ratio | 6.1 | ||
| Altman-Z | -0.14 |
F-Score2
WACC9.63%
ROIC/WACCN/A
Cap/Depr(3y)62.66%
Cap/Depr(5y)107.17%
Cap/Sales(3y)3.93%
Cap/Sales(5y)4.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2820%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-165%
EPS Next Y-91.02%
EPS Next 2Y-22.94%
EPS Next 3Y-10.31%
EPS Next 5Y-0.68%
Revenue 1Y (TTM)-43.77%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-66.83%
Revenue Next Year-57.23%
Revenue Next 2Y-12.53%
Revenue Next 3Y-7.48%
Revenue Next 5Y-3.32%
EBIT growth 1Y-481.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-77.07%
EBIT Next 3Y-18.17%
EBIT Next 5Y-12.61%
FCF growth 1Y-254.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-245.99%
OCF growth 3YN/A
OCF growth 5YN/A